

ZEPBOUND - (10MG/2.4ML, 20MG/2.4ML, 30MG/2.4ML, 40MG/2.4ML, 50MG/2.4ML, 60MG/2.4ML ; Solution)

Generic Name	TIRZEPATIDE	Innovator	Eli Lilly
Dosage	10MG/2.4ML, 20MG/2.4ML, 30MG/2.4ML, 40MG/2.4ML, 50MG/2.4ML, 60MG/2.4ML ; Solution	Branded US Sales	Less Than \$1000 mn
Probable FTF	None	Known Para IV Filers	None
Other ANDA developers	None	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	ZEPBOUND™ is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: • 30 kg/m ² or greater (obesity) or • 27 kg/m ² or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease).		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

ZEPBOUND - (10MG/2.4ML (4.17MG/ML), 20MG/2.4ML (8.33MG/ML), 30MG/2.4ML (12.5MG/ML), 40MG/2.4ML (16.7MG/ML), 50MG/2.4ML (20.8MG/ML), 60MG/2.4ML (25MG/ML); SOLUTION)

Generic Name	TIRZEPATIDE	Innovator	None
Dosage	10MG/2.4ML (4.17MG/ML), 20MG/2.4ML (8.33MG/ML), 30MG/2.4ML (12.5MG/ML), 40MG/2.4ML (16.7MG/ML), 50MG/2.4ML (20.8MG/ML), 60MG/2.4ML (25MG/ML); SOLUTION	Branded US Sales	Less Than \$1000 mn
Probable FTF	None	Known Para IV Filers	None
Other ANDA developers	None	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	ZEPBOUND™ is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: • 30 kg/m ² or greater (obesity) or • 27 kg/m ² or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease).		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.